Meristem Family Wealth’s Jazz Pharmaceuticals JAZZ Stock Holding History

Meristem Family Wealth’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,072	Closed	-$270K	–	413
2021 Q3	$270K	Sell	2,072 -362	-15%	-$54.7K	0.03%	334
2021 Q2	$432K	Buy	+2,434	New	+$422K	0.07%	183

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Meristem Family Wealth's JAZZ Position: Q4 2021 in Review

Meristem Family Wealth sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2021, closing a stake of 2,072 shares — an estimated $270K sold.

Meristem Family Wealth first reported a position in JAZZ in Q2 2021 and held it in 2 quarters. The position peaked at $432K in Q2 2021. 454 funds tracked by Wall St. Rank hold JAZZ as of Q4 2021.

Meristem Family Wealth reported no remaining Jazz Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Meristem Family Wealth sold 2,072 Jazz Pharmaceuticals shares in Q4 2021, an estimated $270K.
Meristem Family Wealth first reported a position in Jazz Pharmaceuticals in Q2 2021 and held it in 2 quarters.
Meristem Family Wealth's Jazz Pharmaceuticals position peaked at $432K in Q2 2021.
454 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2021.

Based on Meristem Family Wealth's 13F filing for Q4 2021, filed 10 Feb 2022.